This study investigates the safety and efficacy of epalrestat, an aldose reductase inhibitor, in SORD-CMT2 patients and second to “The Safety and Tolerability of CLZ-2002 in Patients with Charcot-Marie Tooth Disease” (NCT05947578). This evidence concerns the gene AKR1B1 and Charcot-Marie-Tooth disease.